Integra LifeSciences Holdings Corp. (NASDAQ:IART) CEO Peter J. Arduini sold 24,009 shares of the company’s stock in a transaction dated Tuesday, November 8th. The stock was sold at an average price of $79.51, for a total transaction of $1,908,955.59. Following the completion of the transaction, the chief executive officer now owns 25,593 shares of the company’s stock, valued at approximately $2,034,899.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) opened at 79.93 on Friday. The stock has a market cap of $2.99 billion, a PE ratio of 52.07 and a beta of 0.76. Integra LifeSciences Holdings Corp. has a 52 week low of $54.75 and a 52 week high of $88.86. The company’s 50-day moving average is $81.58 and its 200 day moving average is $79.76.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last issued its earnings results on Thursday, October 27th. The company reported $0.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.89 by $0.04. The business had revenue of $250.30 million for the quarter, compared to the consensus estimate of $249.30 million. Integra LifeSciences Holdings Corp. had a net margin of 6.09% and a return on equity of 16.11%. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.75 earnings per share. Analysts forecast that Integra LifeSciences Holdings Corp. will post $3.50 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Integra LifeSciences Holdings Corp. (NASDAQ:IART)

A number of brokerages have weighed in on IART. Argus upped their price objective on shares of Integra LifeSciences Holdings Corp. from $90.00 to $105.00 and gave the stock a “buy” rating in a research report on Friday, September 23rd. Piper Jaffray Cos. restated an “overweight” rating and set a $94.00 price target (up previously from $86.00) on shares of Integra LifeSciences Holdings Corp. in a research report on Sunday, August 21st. Jefferies Group restated a “buy” rating and set a $95.00 price target on shares of Integra LifeSciences Holdings Corp. in a research report on Tuesday, September 27th. Zacks Investment Research downgraded shares of Integra LifeSciences Holdings Corp. from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Finally, TheStreet downgraded shares of Integra LifeSciences Holdings Corp. from a “buy” rating to a “hold” rating in a research report on Friday, September 30th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Integra LifeSciences Holdings Corp. has a consensus rating of “Buy” and an average target price of $90.38.

Several hedge funds have recently modified their holdings of IART. Silvercrest Asset Management Group LLC increased its stake in shares of Integra LifeSciences Holdings Corp. by 3.0% in the first quarter. Silvercrest Asset Management Group LLC now owns 684,117 shares of the company’s stock valued at $46,082,000 after buying an additional 19,614 shares during the last quarter. Falcon Point Capital LLC increased its stake in shares of Integra LifeSciences Holdings Corp. by 6.3% in the second quarter. Falcon Point Capital LLC now owns 134,293 shares of the company’s stock valued at $10,714,000 after buying an additional 7,934 shares during the last quarter. Panagora Asset Management Inc. increased its stake in shares of Integra LifeSciences Holdings Corp. by 1.7% in the first quarter. Panagora Asset Management Inc. now owns 183,866 shares of the company’s stock valued at $12,385,000 after buying an additional 3,114 shares during the last quarter. RS Investment Management Co. LLC purchased a new stake in shares of Integra LifeSciences Holdings Corp. during the second quarter valued at $56,604,000. Finally, Mesirow Financial Investment Management Equity Management purchased a new stake in shares of Integra LifeSciences Holdings Corp. during the second quarter valued at $10,359,000. 87.46% of the stock is currently owned by institutional investors and hedge funds.

About Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

5 Day Chart for NASDAQ:IART

Receive News & Stock Ratings for Integra LifeSciences Holdings Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corp. and related stocks with our FREE daily email newsletter.